https://doi.org/10.4081/ejh.2023.3688
Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
Submitted: 21 February 2023
Accepted: 17 April 2023
Published: 26 April 2023
Accepted: 17 April 2023
Abstract Views: 420
PDF: 328
HTML: 15
HTML: 15
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The details of immune molecules' expression in desmoid tumors (DTs) remain unclear. This study aimed to determine the expression status of the programmed death-1/programmed death ligand 1 (PD1/PD-L1) immune checkpoint mechanism in DTs. The study included patients with DTs (n=9) treated at our institution between April 2006 and December 2012. Immunostaining for CD4, CD8, PD-1, PD-L1, interleukin-2 (IL-2), and interferon-gamma (IFN-γ) was performed on pathological specimens harvested during the biopsy. The positivity rate of each immune component was calculated as the number of positive cells/total cells. The positivity rate was quantified and correlations between the positivity rates of each immune molecule were also investigated. Immune molecules other than PD-1 were stained in tumor cells and intra-tumor infiltrating lymphocytes. The mean ± SD expression rates of β-catenin, CD4, CD8, PD-1, PD-L1, IL-2, and IFN-ɤ were 43.9±18.9, 14.6±6.80, 0.75±4.70, 0±0, 5.1±6.73, 8.75±6.38, and 7.03±12.1, respectively. The correlation between β-catenin and CD4 was positively moderate (r=0.49); β-catenin and PD-L1, positively weak (r=0.25); CD4 and PD-L1, positively medium (r=0.36); CD8 and IL-2, positively medium (r=0.38); CD8 and IFN-ɤ, positively weak (r=0.28); and IL-2 and IFN-ɤ, positively medium (r=0.36). Our findings suggest that PD-L1-centered immune checkpoint mechanisms may be involved in the tumor microenvironment of DTs.
Tsukamoto S, Takahama T, Mavrogenis AF, Tanaka Y, Tanaka Y, Errani C. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review. Musculoskelet Surg 2023;107:7-18.
DOI: https://doi.org/10.1007/s12306-022-00738-x
Prete F, Rotelli M, Stella A, Calculli G, Sgaramella LI, Amati A, et al. Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis. Clin Exp Med 2022. Online Ahead of Print.
DOI: https://doi.org/10.1007/s10238-022-00849-6
Bansal A, Goyal S, Goyal A, Jana M. WHO classification of soft tissue tumours 2020: an update and simplified approach for radiologists. Eur J Radiol 2021;143:109937.
DOI: https://doi.org/10.1016/j.ejrad.2021.109937
Raveendranadh A, Goutham M, Gowda C, Hegde K, Monappa V, Rodrigues G. Anterior abdominal wall metastasis following curative resection and chemoradiation of rectal cancer masquerading as a desmoid tumour: a clinical conundrum. J Taibah Univ Med Sci 2022;17:146-9.
DOI: https://doi.org/10.1016/j.jtumed.2021.09.001
Siozopoulou V, Marcq E, Jacobs J, Zwaenepoel K, Hermans C, Brauns J, et al. Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. Cancer Immunol Immunother 2019;68:1573-83.
DOI: https://doi.org/10.1007/s00262-019-02390-0
Zhao J, Cheng F, Yao Z, Zheng B, Niu Z, He W. Surgical management of a giant desmoid fibromatosis of abdominal wall with vessels invasion in a young man: a case report and review of the literature. Front Surg 2022;9:851164.
DOI: https://doi.org/10.3389/fsurg.2022.851164
Lazar AJF, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-27.
DOI: https://doi.org/10.2353/ajpath.2008.080475
Sanchez-Mete L, Ferraresi V, Caterino M, Martayan A, Terrenato I, Mannisi E, et al. Desmoid tumors characteristics, clinical management, active surveillance, and description of our FAP case series. J Clin Med 2020;9:4012.
DOI: https://doi.org/10.3390/jcm9124012
Aelvoet AS, Struik D, Bastiaansen BAJ, Bemelman WA, Hompes R, Bossuyt PMM, et al. Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis. Fam Cancer 2022;21:429-39.
DOI: https://doi.org/10.1007/s10689-022-00288-y
Escobar C, Munker R, Thomas JO, Li BD, Burton GV. Update on desmoid tumors. Ann Oncol 2012;23:562-9.
DOI: https://doi.org/10.1093/annonc/mdr386
Al-Jazrawe M, Au M, Alman B. Optimal therapy for desmoid tumors: current options and challenges for the future. Expert Rev Anticancer Ther 2015;15:1443-58.
DOI: https://doi.org/10.1586/14737140.2015.1096203
Tsukamoto S, Tanzi P, Mavrogenis AF, Akahane M, Kido A, Tanaka Y, et al. Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors. BMC Musculoskelet Disord 2021;22:12.
DOI: https://doi.org/10.1186/s12891-020-03897-9
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
DOI: https://doi.org/10.1038/nm730
Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190-8.
DOI: https://doi.org/10.1593/neo.05733
Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015;37:764-82.
DOI: https://doi.org/10.1016/j.clinthera.2015.02.018
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018;6:8.
DOI: https://doi.org/10.1186/s40425-018-0316-z
Hashimoto K, Nishimura S, Ito T, Akagi M. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. Eur J Histochem 2021;65:3203.
DOI: https://doi.org/10.4081/ejh.2021.3203
Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, et al. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. Mol Oncol 2017;11:1495-507.
DOI: https://doi.org/10.1002/1878-0261.12101
Kaewkangsadan V, Verma C, Eremin JM, Cowley G, Ilyas M, Eremin O. Crucial contributions by T lymphocytes (effector, regulatory, and checkpoint inhibitor) and cytokines (TH1, TH2, and TH17) to a pathological complete response induced by neoadjuvant chemotherapy in women with breast cancer. J Immunol Res 2016;2016:4757405.
DOI: https://doi.org/10.1155/2016/4757405
Kakavand H, Wilmott JS, Long GV, Scolyer RA. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology 2016;48:194-202.
DOI: https://doi.org/10.1016/j.pathol.2015.12.010
Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577:556-60.
DOI: https://doi.org/10.1038/s41586-019-1906-8
Hu-Lieskovan S, Ribas A. New combination strategies using programmed cell death 1/programmed cell death ligand 1 checkpoint inhibitors as a backbone. Cancer J 2017;23:10-22.
DOI: https://doi.org/10.1097/PPO.0000000000000246
Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-20.
DOI: https://doi.org/10.1038/sj.onc.1203041
Gebert C, Hardes J, Kersting C, August C, Supper H, Winkelmann W, et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007;50:491-7.
DOI: https://doi.org/10.1111/j.1365-2559.2007.02619.x
Ethics Approval
The current study was approved by the Kindai University Ethics Committee (N. 31-187; Date 16 January 2020)How to Cite
Hashimoto, K., Nishimura, S., Shinyashiki, Y., Ito, T., Kakinoki, R., & Akagi, M. (2023). Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors. European Journal of Histochemistry, 67(2). https://doi.org/10.4081/ejh.2023.3688
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- P. Narducci, R. Bortul, R. Bareggi, V. Nicolin, Clathrin-dependent endocytosis of membrane-bound RANKL in differentiated osteoclasts , European Journal of Histochemistry: Vol. 54 No. 1 (2010)
- Francesca Diomede, Soundara Rajan Thangavelu, Ilaria Merciaro, Monica D'Orazio, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani, Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation , European Journal of Histochemistry: Vol. 61 No. 3 (2017)
- Liying Shen, Kongjie Lu, Zhenfeng Chen, Yingwei Zhu, Cong Zhang, Li Zhang, Pre-treatment with galectin-1 attenuates lipopolysaccharide-induced myocarditis by regulating the Nrf2 pathway , European Journal of Histochemistry: Vol. 67 No. 4 (2023)
- G. Natale, E. Pompili, F. Biagioni, S. Paparelli, P. Lenzi, F. Fornai, Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases , European Journal of Histochemistry: Vol. 57 No. 1 (2013)
- Yanmei Yao, Leqing Lin, Wenxue Tang, Yueliang Shen, Fayu Chen, Ning Li, Baiyong Wang, Pretreatment with geniposide mitigates myocardial ischemia/reperfusion injury by modulating inflammatory response through TLR4/NF-κB pathway , European Journal of Histochemistry: Vol. 67 No. 3 (2023)
- N. Kiga, I. Tojyo, T. Matsumoto, Y. Hiraishi, Y. Shinohara, S. Fujita, Expression of lumican related to CD34 and VEGF in the articular disc of the human temporomandibular joint. , European Journal of Histochemistry: Vol. 54 No. 3 (2010)
- M. Di Rosa, M.A. Szychlinska, D. Tibullo, L. Malaguarnera, G. Musumeci, Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A morphological study , European Journal of Histochemistry: Vol. 58 No. 3 (2014)
- Ermanna Turano, Federica Virla, Ilaria Scambi, Sylwia Dabrowska, Oluwamolakun Bankole, Raffaella Mariotti, Adipose mesenchymal stem cells-derived extracellular vesicles exert their preferential action in damaged central sites of SOD1 mice rather than peripherally , European Journal of Histochemistry: Vol. 68 No. 3 (2024)
- S. San Martin, J. Fitzgerald, M. Weber, M. Párraga, T. Sáez, T.M. Zorn, U.R. Markert, STAT3 and SOCS3 expression patterns during murine placenta development , European Journal of Histochemistry: Vol. 57 No. 2 (2013)
- Wenjing Liu, Shanshan Ming, Xiaobing Zhao, Xin Zhu, Yuxiang Gong, Developmental expression of high-mobility group box 1 (HMGB1) in the mouse cochlea , European Journal of Histochemistry: Vol. 67 No. 3 (2023)
<< < 3 4 5 6 7 8 9 10 11 12 > >>
You may also start an advanced similarity search for this article.
